Dr. Beauregard is an assistant professor in the Department of Radiology and Nuclear Medicine at Laval University, a clinician scientist in the Oncology axis of the CHU Research Centre of Quebec – Laval University, and a specialist in nuclear medicine in the Department of Medical Imaging of the CHU of Quebec. Dr. Jean-Mathieu Beauregard completed his residency in nuclear medicine and his master’s degree in radiobiology at the Université de Sherbrooke. He completed additional training at the Peter MacCallum Cancer Centre in Melbourne, Australia from 2007 to 2010, during which he developed a strong interest in molecular imaging and radionuclide therapy for neuroendocrine tumors. Since his return to the CHU of Quebec, he has set up a new radiopeptide therapy program for neuroendocrine tumors. His research program is multidisciplinary and integrates translational research projects in medical and clinical physics.

Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.

At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.

In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.

Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.

L'Hôtel-Dieu de Québec
9, rue McMahon
Québec, Québec
Canada G1R 3S3
31 entries « 1 of 7 »

Schneider JR, Shatzkes DR, Scharf SC, Tham TM, Kulason KO, Buteau FA, Del Prete M, Chakraborty S, Anderson TA, Asiry S, Beauregard JM, Langer DJ, Costantino PD, Boockvar JA

Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma.

Journal Article

Oper Neurosurg (Hagerstown), 15 (6), pp. 100-109, 2018.

Abstract | Links:

Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial.

Journal Article

Eur J Nucl Med Mol Imaging, 2018, ISSN: 1619-7070.

Abstract | Links:

Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT.

Journal Article

EJNMMI Phys, 5 (1), pp. 25, 2018, ISSN: 2197-7364.

Abstract | Links:

Arsenault F, Beauregard JM, Pouliot F

Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.

Journal Article

Curr Opin Support Palliat Care, 12 (3), pp. 359-365, 2018, ISSN: 1751-4258.

Abstract | Links:

Purohit NK, Shah RG, Adant S, Hoepfner M, Shah GM, Beauregard JM

Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.

Journal Article

Oncotarget, 9 (37), pp. 24693-24706, 2018, ISSN: 1949-2553.

Abstract | Links:

31 entries « 1 of 7 »

Active projects

  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Personalizing Radionuclide Therapy of Neuroendocrine Tumours., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement : Concours transitoire de subvention de fonctionnement : 2014-2015, from 2015-07-01 to 2019-06-30
  • Upregulating expression of SSTR to enhance PRRT of neuroendocrine tumors, Subvention, L'Institut de recherche de la Société canadienne du cancer, Subventions pour l'innovation, from 2017-02-01 to 2020-01-31

Recently finished projects

  • (FRSQ 72307) Amélioration de la thérapie radionucléidique des tumeurs neuroendocrines, Subvention, Fondation du CHU de Québec, from 2016-03-22 to 2017-03-21
  • (FRSQ 74849) Projet de recherche sur l'amélioration de la thérapie radionucléidique des tumeurs neuroendocrines , Subvention, Fondation du CHU de Québec, from 2016-04-01 to 2017-03-31
  • Acquisition of a pre-clinical positron emission tomography (PET) camera and a radiosynthesis unit, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2014-09-01 to 2017-12-31
  • Améliorer la thérapie radionucléidique ciblée des tumeurs neuroendocrines par la personnalisation du traitement et la radiosensibilisation tumorale, Subvention, Fonds de recherche du Québec - Santé, Établissement de jeunes chercheurs - Juniors 1, from 2012-07-01 to 2016-06-30
  • Améliorer la thérapie radionucléidique ciblée des tumeurs neuroendocrines par la personnalisation du traitement et la radiosensibilisation tumorale., Subvention, Fonds de recherche du Québec - Santé, Chercheurs-boursiers cliniciens - Juniors 1 et 2, Seniors, from 2012-07-01 to 2016-06-30
  • Bourse de soutien, Subvention, Université Laval - démarrage nouveau chercheur, Soutien facultaire aux jeunes chercheurs de la Faculté de médecine, from 2016-04-01 to 2017-03-31
  • PARP-inhibitor radiosensitization in 177Lu-octreotate PRRT of neuroendocrine tumors, Subvention, Société des tumeurs Carcinoïdes-NeuroEndocrines du Canada, from 2016-07-01 to 2018-06-30
  • PROPS: PET/MRI pre-Radiotherapy for Post-Prostatectomy Salvage., Subvention, Cancer de la prostate Canada, Subventions d'équipe Movember (Movember Discovery Grants), from 2014-01-01 to 2016-06-30
Data provided by the Université Laval research projects registery